Fang Sheng Pharmaceutical (603998.SH) subsidiary's traditional Chinese medicine innovative drug research and development project has received the drug clinical trial approval notice.

SooTruly Finance and Economics App News, Fosun Pharmaceutical (603998.SH) has announced that its holding subsidiary Guangdong Fosun Rongke Pharmaceutical Co., Ltd. (referred to as "Fosun Rongke") recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration for its traditional Chinese medicine innovative drug research and development project Ziyin Granule.